Evidence map›Paper›PMID 31023386›Full record

SynthesisBMC pharmacology & toxicology2019

Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.

Yingxu Ma, Fan Bai, Fen Qin, Jiayi Li, Na Liu, Dongping Li, Tengfang Li, Hui Xie, Da Liu, Shenghua Zhou and 1 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pharmacology & toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Review
  16. Review
  17. Anthracycline Toxicity: Light at the End of the Tunnel?Annual review of pharmacology and toxicology · 2024
    Review
  18. Article
  19. Review
  20. New Concepts in Cardio-Oncology.Cancer treatment and research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yingxu MaDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Fan BaiDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Fen QinDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Jiayi LiDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Na LiuDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Dongping LiDepartment of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Tengfang LiUrological Organ Transplantation Department, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Hui XieDepartment of Cardiothoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Da LiuDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Shenghua ZhouDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Qiming LiuDepartment of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. qimingliu@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effects of β blockers on the primary prevention of anthracycline-induced cardiotoxicity were controversial.

methodsWe searched PubMed, Embase and Cochrane Library for randomized controlled trials of the comparison of β blockers versus placebo in patients undergoing anthracycline chemotherapy. This meta-analysis was performed by using random-effect models.

resultsNine hundred forty participants from 11 trials were included in this meta-analysis. β blockers led to a significant reduction in symptomatic heart failure (risk ratio [RR] 0.29, 95% CI 0.10 to 0.85). Compared with placebo, β blockers were associated with improved left ventricular ejection fraction (mean difference [MD] 4.46, 95% CI 1.77 to 7.15) and s' (MD 0.78, 95% CI 0.01 to 1.55) in parallel with reduced left ventricular diameter (left ventricular end systolic diameter, MD -3.19, 95% CI -6.17 to - 0.21; left ventricular end diastolic diameter, MD -2.28, 95% CI 4.50 to - 0.05). β blockers also improved strain and strain rate when compared with placebo. There were no significant differences in diastolic function variables between β blockers and placebo except e' (MD 2.33, 95% CI 0.16 to 4.51). In addition, β blockers compared with placebo reduced the risk of cardiac troponin I elevation > 0.04 ng/ml (RR 0.60, 95% CI 0.42 to 0.85). There was no marked difference in adverse events (RR 0.94, 95% CI 0.56 to 1.59) between β blockers and placebo.

conclusionsIn cancer patients with anthracycline therapy, prophylactic β blockers were associated with reduced risk of heart failure, decreased left ventricular diameter, improved left ventricular systolic function, and alleviative cardiomyocyte injury.

Indexed as

Adrenergic beta-AntagonistsAnthracyclinesAntibiotics, AntineoplasticCardiotoxicityHumansNeoplasmsPrimary PreventionRandomized Controlled Trials as TopicAdrenergic beta-AntagonistsAnthracyclinesAntibiotics, AntineoplasticAnthracyclineCardiotoxicityPrimary preventionβ blockers

Identifiers

PMID31023386
PMCPMC6485127
OpenAlexW2943871401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.